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Background: The effectiveness of inhaled salbutamol in routine care depends particularly on prescribed dosage
and applied inhalation technique. To achieve maximum effectiveness and to prevent drug-related problems,
prescription and administration need to work in concert.
Methods: We performed a controlled intervention pilot study with 4 consecutive groups in a general paediatric
unit and assessed problems in salbutamol prescribing and administration. Control group [i]: Routine care without
additional support. First intervention group [ii]: We carried out a teaching session for nurses aimed at preventing
problems in inhalation technique. Independently from this, a pharmacist counselled physicians on problems in
salbutamol prescribing. Second intervention group [iii]: Additionally to the first intervention, physicians received
standardised feedback on the inhalation technique. Follow-up group [iv]: Subsequently, without any delay after the
second intervention group had been completed, sustainability of the measures was assessed. We performed the
chi-square test to calculate the level of significance with p≤ 0.05 to indicate a statistically significant difference for
the primary outcome. As we performed multiple testing, an adjusted p≤ 0.01 according to Bonferroni correction
was considered as significant.
Results: We included a total of 225 patients. By counselling the physicians, we reduced the number of patients
with problems from 55% to 43% (control [i] vs. first intervention [ii], n.s.). With additional feedback to physicians, this
number was further reduced to 25% ([i] vs. [iii], p < 0.001). In the follow-up [iv], the number rose again to 48%
(p < 0.01 compared to feedback group).
Conclusions: Teaching nurses, counselling physicians, and providing feedback on the quality of inhalation
technique effectively reduced problems in salbutamol treatment. However, for success to be sustained, continuous
support needs to be provided.
Trial registration: German Clinical Trials register: DRKS00006792.
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Children are prone to preventable adverse drug events
caused by drug-related problems (DRP). The rate of
those events in this patient group is three times higher
than in adults and 79% of potential adverse drug events
occur in prescribing [1]. Although these results have
been reported, data on the actual rate of prescribing er-
rors in paediatrics is scarce [2]. Ghaleb et al. found pre-
scribing error rates of up to 31% in children [3]. One of
the main problems in paediatric prescribing is patient-
individualized dosing. Published dosage recommenda-
tions for children, however, are very heterogeneous [4].
This applies especially to salbutamol which rates amongst
the most frequently prescribed drugs in children [5,6].
The optimal dosage of salbutamol in children is contested
[7,8] and imprecise dosing instructions may lead to DRP.
Additionally, the medication’s effectiveness does not only
depend on the prescribed dosage but also on the patient’s
inhalation technique [9]. Various methods such as guide-
line implementation, teaching programmes, ward round
services by pharmacists, and electronic prescribing are de-
scribed to solve DRP [10-14]. Existing studies focus either
on prescription or administration. Several studies dealing
separately with both processes exist. To the best of our
knowledge, however, no studies on the effects of inter-
vention strategies addressing the interrelation between
prescription and administration have been published.
Therefore, we performed a controlled interventional
study with 4 consecutive groups: [i] control (no add-
itional support, routine care), [ii] first intervention (im-
plementation of an internal guideline, training sessions
for nurses, pharmaceutical counselling), [iii] second
intervention (additional feedback to the prescribing
physicians on the quality of the inhalation processes)
and [iv] follow-up (termination of all additional support,
routine care).
Thus, we linked prescription and administration by a
standardised flow of information to the prescribing phy-
sicians and investigated its benefit.
Methods
Setting
This pilot study was performed in a general paediatric
unit with 22 beds of a university hospital. The unit fo-
cused among others on pulmonary diseases. Compu-
terised physician order entry, a clinical decision support
system, unit dose, or other pharmaceutical services were
not yet implemented in this unit.
Inclusion and exclusion criteria
We included all consecutive patients with salbutamol
prescriptions who had been admitted to the participating
unit due to bronchial obstruction or asthma. No add-
itional examinations/laboratory data were required forinclusion. Patients with a hospital stay restricted to one
weekend were excluded because the pharmaceutical
counselling was offered on weekdays only.
Definitions
Drug-related problem (DRP)
DRP refers to deviations from an internal guideline on
bronchial obstruction or inadequate documentation such
as incomplete prescriptions (e.g. missing single dose or
frequency), incomprehensible or ambiguous prescrip-
tions, or not clearly marked discontinued medications.
Guideline
An internal guideline addressed appropriate drug pre-
scription and dosing in children suffering from obstruct-
ive lung diseases and asthma including standardised
salbutamol treatment. This guideline was developed by an
interdisciplinary expert panel and was put into practice at
the beginning of the first intervention group of this study.
The guideline was based on the national guideline on the
treatment of asthma [15]. Furthermore, our guideline in-
cluded two dose regimens: a regular salbutamol dose treat-
ment regimen and a high dose regimen for children
suffering from severe obstruction or with insufficient in-
halation technique (Table 1). Doses exceeding this high
dose regime were defined as elevated doses.
Expert panel
The expert panel was composed of three pharmacists
and four paediatricians, among them the head of the
local Pediatric Pneumology Section. The panel was in
charge of developing the internal guideline.
Monitoring of inhalation technique
Two pharmacists monitored and analysed the quality of
patients’ inhalation processes. Patient-individual parame-
ters such as breathing coordination, cooperation during
inhalation process, and body position were rated. We
also assessed device specific administration rules such as
sufficient number of breaths in case of using a spacer,
air-tight fit of mask/mouthpiece, and proper shaking of
metered dose inhaler (MDI).
Teaching session (for nurses)
A teaching session for nurses was developed and imple-
mented to reach “best practice” in inhalation technique.
We offered a 60-minute teaching session, in which a
pharmacist explained inhalation handling guidelines and
provided background information on the impact of the
inhalation technique on clinical outcomes. The teaching
session focused on the correct use of nebuliser and MDI
with and without spacer as well as on the question of
how to conduct an optimal inhalation maneuver with
children. We offered the teaching session five times in
Table 1 Excerpt of the internal guideline: recommendations on treatment of bronchial obstruction
Inhaler device Children <12 years Children >12 years Interval (minimum)
Regular dosage regimen Nebulization (1 drop = 0,25 mg) 1-2 drops per life year, min. single dose 3 drops
(recommendation by the local Pediatric Pneumology
Section), max. single dose 8 drops; 3-4 times/day
5-10 drops, 3-5 times/day, max. daily dose 50 drops 4 hours
Metered dose inhaler (MDI)
(1 puff = 100 μg)
1 puff 3-4 times/day; as needed up to 6 puffs/day 1-2 puffs 3-4 times/day; as needed up to
12 puffs/day
3 hours
High dosage regimen • Recommendation in cases of severe obstruction or insufficient inhalation technique
according to the local Pediatric Pneumology Section: 2 puffs 6 times/day (MDI)
• Note: inform family/carer on off-label use; higher doses need to be discussed with a senior physician
General remarks • Children <5 years: prefer MDI with spacer (use facemask if necessary)
• Increased single dose/frequency possible as needed for symptoms in individual cases (off-label)
• Good response to salbutamol/recovery from symptoms: reduce interval between
inhalations to 3 hours (MDI) or 4 hours (nebulization)
• No oral β2-agonists in acute situations
Disclaimer • The recommendations cover only routine care situations, in individual cases therapy has to
be adjusted to the individual needs.
• The therapy decision is the sole responsibility of the prescribing physician.
• This information does not replace the approved summary of product characteristics.
Legend: if not stated otherwise: dosage approved by the national authority.
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Table 2 Characteristics of included patients with
salbutamol treatment of bronchial obstruction or asthma
Control
group
Counselling
group
Feedback
group
Follow-up
group
Total number
of patients
56 56 57 56
Among them female 22 (39%) 21 (38%) 18 (32%) 19 (34%)
Median age
in years
1.27 1.21 0.67 1.47
Q25/75 0.41/3.55 0.35/2.40 0.34/1.88 0.62/4.56
Minimum/maximum 0.30/14.03 0.06/14.68 0.10/13.86 0.03/17.81
Legend: data is presented as median with first (25%) and third (75%) quartile
(Q25/Q75); there are no differences in sex or age between the four groups
(p-values not significant).
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to take the session. Furthermore, nurses had the oppor-
tunity to ask the pharmacists for advice during the mon-
itoring. All nurses working in the unit during the study
were invited to take part in the study.
Counselling service (for physicians)
A pharmacist assessed salbutamol prescriptions each day
and advised prescribing physicians as regards DRP and
possibilities to solve them during the next morning ward
round. The pharmacist’s recommendation was patient-
individualised in respect to the patient’s physical and
clinical condition. This strategy focused on the appropri-
ateness of prescribed dosing.
Feedback service (for physicians)
In addition to providing a counselling service, pharma-
cists reported to the physicians the quality of inhalation
technique assessed by monitoring. To standardise this
feedback a structured reporting form on the monitored
items was filed into the patient’s chart. This information
on patient’s personal inhalation abilities in addition to the
patient’s physical and clinical condition allows patient-
individual recommendations on salbutamol prescribing.
Study protocol
Following approval by the Ethics Committee of the
University of Leipzig, Leipzig, Germany, and the re-
sponsible employee committee, we performed a pro-
spective controlled interventional pilot study focusing
on salbutamol prescribing. Primary outcome was the
number of patients with at least one predefined DRP in
their salbutamol prescribing.
The study consisted of 4 consecutive groups: [i] control
group (no additional support, routine care), [ii] counselling
group (with teaching the nurses, implementation of the in-
ternal guideline and counselling service for the physicians,
additionally to routine care), [iii] feedback group (with
monitoring of the nurses, counselling and feedback service
for the physicians, additionally to routine care) and [iv] a
follow-up group (any additional support was terminated,
routine care only). The follow-up was performed subse-
quently without any delay after the feedback group had
been completed.
An additional teaching session was offered at the be-
ginning of the counselling group to inform all physicians
about the aim of the study and to explain the instru-
ments of the study programme, especially the newly de-
veloped guideline. Furthermore, the guideline was placed
at the medical trolley in the unit and sent by email to
the concerned physicians. The counselling service and
data collection was launched in the week after the
teaching session.Power calculation and data analysis
Considering similar studies of our group [16] and our
experience in this study setting, we assumed that in
around 55% of the patients at least one DRP would
occur. A relative reduction of at least 50% after the full
intervention programme (counselling and feedback service)
was considered clinically relevant (i.e. a rate of ≤27.5% in
the feedback group, primary outcome). Assuming rates in
this range, a two-sided chi-square test at significance level
of α = 0.05 and sample size of 41 per group would provide
a power of 1 − β = 0.80 for the primary endpoint (calculated
by G*Power Version 3.1.7, Franz Faul, University of Kiel,
Germany [17]).
Data is presented as median with first (25%) and third
(75%) quartile (Q25/Q75) and minimum/maximum as
appropriate. We performed the Kruskal-Wallis-test or
chi-square test as appropriate with Kyplot® (KyensLab,
Tokyo, Japan) to calculate the level of significance with
p ≤ 0.05 considered to indicate a statistically significant
difference for the primary outcome. As we performed
multiple testing, we applied the Bonferroni correction
and considered an adjusted p ≤ 0.01 as significant. Inter-
rater agreement was calculated with Cohen's kappa.
Kappa values (κ) of 0.81-1.00 represent very good agree-
ment between two different monitors.Results
We included patients as shown in Table 2.
By counselling the prescribing physicians [ii], we re-
duced the number of patients with DRP from 55% (31 of
56 patients, control group [i]) to 43% (24/56, n.s.). Add-
itional feedback [iii] led to a further decrease in the
number of patients with DRP as the primary outcome to
25% (14/57; p < 0.001 compared to control group [i],
Figure 1). After termination of any additional support,
the number of patients with DRP increased again to 48%
(27/56) in the follow-up [iv] (p < 0.01 compared to feed-
back group [iii]).
Figure 1 Patients with drug-related problems (DRP) in prescription
in their salbutamol treatment. DRP refers to deviations from an
internal guideline or inadequate documentation [incomplete
prescriptions (e.g. missing single dose or frequency), incomprehensible
or ambiguous prescriptions, not clearly marked discontinued
medications]. n (Control group) = 56, n (Counselling group) = 56,
n (Feedback group) = 57, n (Follow-up group) = 56.
Table 4 Positive feedback to the prescribing physicians on
the quality of the inhalation processes in the feedback
group
Item All processes
(MDI + nebulizer)
MDI Nebulizer
Total number
of processes
255 156 99
Device specific
administration rules
Good airtight fit
of mask/mouthpiece
202 (79%) 137 (88%) 65 (67%)
MDIa shaken before
administration
- 141 (90%) -
Sufficient number
of breaths when
using a spacer
- 113 (72%) -
Patient-individual
parameters
Good upright body position 101 (40%) 67 (43%) 34 (34%)
Good cooperationb 148 (58%) 77 (49%) 71 (72%)
Good breathing
coordination
19 (7%) 13 (8%) 6 (6%)
aMDI: Metered Dose Inhaler bGood cooperation was defined as patient’s support of
the administration activities with regard to the age-dependent abilities of the
patient, i.e. for younger children no rejection of the administration process or
correctly attending to the nurses’ instructions for older children and adolescents.
For each monitored inhalation process a reporting form with the assessment of
each of the listed items was filed into the patient’s chart; positive feedback was
forwarded if the administration processes were appropriate in the respective item
and a negative feedback in cases if administration was inappropriate.
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vated salbutamol doses related to the internal guideline.
The number of patients with elevated doses was 50% (28/
56) in the control group [i], 29% (16/56) in the counselling
group [ii], 18% (10/57) in the feedback group [iii], and 34%
(19/56) in the follow-up group [iv] (Table 3).
We monitored a total of 255 inhalation processes, 156
with a MDI and 99 with a nebulizer. The feedback given
to the physicians is shown in Table 4. For example, proper
shaking of the MDI was reported in 90% of the monitored
inhalation processes.
Inter-rater agreement for the two independent moni-
tors was very good with κ = 0.96.Table 3 Dosing and drug-related problems in prescription
Categoriesa Control
group
Counselling
group
Feedback
group
Follow-up
group
Patients
n (%)
Patients
n (%)
Patients
n (%)
Patients
n (%)
According to guideline
Regular dose regimenb 17 (30) 17 (30) 24 (42) 9 (16)
High dose regimenb 8 (14) 15 (27) 19 (33) 20 (36)
Deviating from
guidelinec
Elevated dosesb 28 (50) 16 (29) 10 (18) 19 (34)
Inadequate
documentation
12 (21) 11 (20) 4 (7) 17 (30)
aMultiple categories possible; bThe guideline included two dose regimens: a
regular salbutamol dose treatment regimen and a high dose regimen for
children suffering from severe obstruction or with insufficient inhalation
technique. Doses exceeding this high dose regime were defined as elevated
doses; cwe did not identify any cases of underdosing.Discussion
Prescription and administration of inhaled drugs cause
major problems in the treatment of obstructive lung dis-
eases [18,19]. Children are of special interest because
they are frequently affected by obstructive lung diseases
requiring appropriate treatment. Age-dependent dosing
is not yet sufficiently investigated by randomized con-
trolled trials. Therefore, in routine practice off-label use
with doses higher than approved without sufficient evi-
dence for better outcomes is frequent [20]. Particularly
inhaled drugs such as salbutamol require additional con-
sideration of the administration technique to decide on
the appropriate dosage. We identified an alarming per-
centage of patients with DRP in salbutamol prescriptions
in routine care [i]. Implementation of a guideline and a
counselling service addressing salbutamol prescription
performed by a pharmacist decreased the high rate of
DRP [ii]. The breakthrough, however, was achieved by
providing additional feedback to physicians addressing the
inhalation technique of the patient assessed by a monitor-
ing [iii]. By implementing a programme that included also
a teaching session for nurses to improve inhalation tech-
nique, a guideline as standard for salbutamol prescribing
and standardised feedback on the inhalation technique, we
particularly prevented the prescription of elevated doses.
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and was no longer detectable after the intervention had
been terminated [iv].
Patient outcomes in obstructive lung diseases in rou-
tine care are not as good as in clinical trials due to poor
inhalation technique [19]. Poor inhalation technique re-
sults inter alia from problems in handling the inhalation
devices or knowledge deficits. Therefore, patients need
special guidance in the inhalation process by healthcare
professionals. However, correct inhaler use was demon-
strated by only 15-69% of healthcare professionals [19].
Their knowledge on correctly using an inhalation device
was also insufficient [21]. Comprehensive education on
inhalation technique decreased deficits in inhalation
technique resulting in improved clinical parameters at
even lower doses than originally applied [22]. To ad-
dress the relation between the prescribed dosage and
administration, we instructed nurses on how to opti-
mise inhalation technique and, simultaneously, we im-
plemented a guideline on the treatment of obstructive
lung diseases for physicians. This is essential, because
the dose finally reaching the patient might be too low to
be effective, if prescribed dosages are reduced without
an improvement of inhalation technique. Otherwise, if
inhalation processes are optimised without adopting the
prescribed salbutamol dose, patients may suffer from
increased adverse drug effects due to elevated salbuta-
mol exposure. Therefore, both processes should be
tuned to each other especially if they undergo changes.
In salbutamol inhalation therapy, the optimal dosage
depends on the inhalation technique, the clinical condi-
tion of the patient and the dosage regimen. In the
counselling group, detailed information on the inhal-
ation technique was not yet available to the physicians.
Thus, daily doses were reduced only to a minor degree.
In the feedback group, the (improved) quality of inhal-
ation technique in the individual patient was reported
to the physicians resulting in reduced prescribed salbu-
tamol doses. Especially the number of patients with
salbutamol doses higher than recommended in the guide-
line was effectively reduced. After the full programme
was implemented, the number of patients treated with
the high dose regimen doubled indicating that those
children were now sufficiently treated with high doses
if necessary, but they were no longer prescribed too
much treatment. The high number of items reported as
“good” in the feedback indicates a successful training.
Due to the very young age of the patients, breathing co-
ordination remains problematic because young chil-
dren do not have the abilities to support the inhalation
process yet.
The benefit of pharmacists in the paediatric setting
has also been discussed by Fortescue et al.: a high degree
of all medication errors in prescribing, transcribing andadministering could be prevented by pharmacists [23].
Furthermore, improved communication between physi-
cians, nurses, and pharmacists was suggested as poten-
tially effective intervention to prevent medication errors
in the same study. We successfully developed and per-
formed an interventional pilot study on evaluating a
comprehensive programme to optimise the information
process by offering standardised feedback on the inhal-
ation technique to the physicians. As a consequence, the
rate of preventable DRP decreased. A mere implementa-
tion of a guideline without any further support in pre-
scription was insufficient as the number of patients
affected by DRP rose again to base level after all add-
itional support had been terminated.Limitations
We assessed DRP in children as a high risk group for
DRP in prescription (off-label use and missing data from
randomised clinical trials) as well as in administration
(children have no or limited abilities to support inhal-
ation actively). Therefore, the results are not transferable
to other patient populations. In our setting, no routine
assessment of safety and effectiveness is documented by
the prescribing physicians. Our intention, however, was
an assessment under routine conditions. We therefore
did not implement any additional assessment instru-
ments. What is more, the implementation of those add-
itional instruments could have influenced the outcomes
themselves. DRP are correlated with the occurrence of
adverse drug reactions and missing effectiveness [13].
Therefore, strategies should intercept DRP to prevent
adverse drug reactions before they actually occur. By
assessing DRP instead of occurring adverse drug reac-
tions we intended to evaluate the “first” parameter on
the cascade to identify potential risks for the patients.
Additionally, this parameter can be identified under
routine conditions. Effectiveness and safety including
recurrence or rehospitalisation, however, are some-
times difficult to be correlated to the actual use of a
drug and requires high numbers of patients to reach
significant levels.
We did not choose a blinded and randomized pro-
cedure. It is difficult to perform blinded teaching inter-
ventions or to randomize patients for interventions
influencing the knowledge and practical performance
of health care professionals treating control and inter-
vention patients at the same time. Therefore, we con-
sidered a cluster randomization for our study including
similar units in different centres in our city. However,
we found in a pre-testing that the settings were quite
different. We did not perform a multicentre study in
different cities with similar units because of the limited
resources of this study.
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We identified a high number of DRP in inhaled salbuta-
mol therapy in routine patient care. By providing a
counselling service at the point of prescription based on
a newly developed and implemented guideline DRP rates
and elevated doses in salbutamol prescription decreased.
Those effects were strongly enhanced by providing feed-
back which passed on information on the inhalation tech-
nique to the prescribing physician: we halved the number
of patients affected by DRP compared to control. To
stabilize those outcomes, however, continuous prescrip-
tion review and counselling as well as reporting on inhal-
ation technique were shown to be necessary to achieve
sustainable effects in routine care.
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